Abby Hardy, Author at BioTuesdays

This Week's Feature

Gritstone bio awaits preliminary Phase 2 data for personalized neoantigen vaccine

Gritstone bio (NASDAQ: GRTS) is expecting in the first quarter of 2024 preliminary data from its Phase 2/3 study evaluating the Company's personalized neoantigen vaccine candidate for the treatment of colorectal cancer...

November 28, 2023

Markets

Evercore starts Gracell Biotech at OP

Evercore ISI initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with an “outperform” rating and no price target. The stock was quoted at $5.43 midday on Nov. 27. Gracell is developing a unique CAR-T construct...

November 27, 2023

Developments

Anixa reports European patent for ovarian cancer vaccine technology

Anixa Biosciences (NASDAQ:ANIX) reported that its partner, Cleveland Clinic, received an intention-to-grant notice from the European Patent Office (EPO) for the patent application covering the company’s ovarian cancer...

November 27, 2023

Developments

SHINE Technologies, Nucleus RadioPharma in long-term supply pact

SHINE Technologies and Nucleus RadioPharma entered a multi-year supply agreement for lutetium-177, a radiopharmaceutical that is used for targeted cancer treatment. Nucleus, a contract development and manufacturing...

November 17, 2023

Developments

PharmaJet launches Phase 1 trial of Precision Delivery Systems-delivered VEE vaccine

PharmaJet launched a Phase 1 clinical study evaluating a Venezuelan Equine Encephalitis (VEE) DNA vaccine delivered via the company’s needle-free Precision Delivery Systems. The Phase 1 trial, sponsored by PharmaJet and...

November 17, 2023

Developments

LENZ Therapeutics, Graphite Bio in merger accord

Closely-held LENZ Therapeutics and Graphite Bio (NASDAQ:GRPH) entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company, which will focus on advancing LENZ’...

November 15, 2023

Developments

IntelGenx gets approval for Phase 2 Montelukast VersaFilm trial in Parkinson’s disease

IntelGenx (TSX:IGX; OTCQB:IGXT) reported that the Swedish Medical Products Agency, the Swedish Ethical Review Authority, and the Regional Biobank Centre approved the company’s planned clinical study to investigate the...

November 14, 2023

Feature

Intrinsic Medicine developing new drugs for gut-immune-brain axis disorders

Closely-held Intrinsic medicine is developing new drugs for diseases that are linked to the disordered interaction of the gut microbiome, the immune system and the nervous system.

November 14, 2023

Developments

Hepion’s rencofilstat demonstrates significant reduction in liver stiffness in patients with advanced MASH liver disease

Hepion Pharmaceuticals (NASDAQ:HEPA) presented new data from its Phase 2 ALTITUDE-NASH trial demonstrating that 17 weeks of rencofilstat treatment significantly reduced liver stiffness in subjects with advanced F3...

November 13, 2023

Markets

Brookline starts Annovis Bio at buy; PT $35

Brookline Capital Markets initiated coverage of Annovis Bio (NASDAQ:ANVS) with a “buy” rating and price target of $35. The stock was quoted at $5.85 midday on Nov. 10. Annovis is developing treatments for...

November 10, 2023

Author - Abby Hardy

Gritstone bio awaits preliminary Phase 2 data for personalized neoantigen vaccine

Evercore starts Gracell Biotech at OP

Anixa reports European patent for ovarian cancer vaccine technology

SHINE Technologies, Nucleus RadioPharma in long-term supply pact

PharmaJet launches Phase 1 trial of Precision Delivery Systems-delivered VEE vaccine

LENZ Therapeutics, Graphite Bio in merger accord

IntelGenx gets approval for Phase 2 Montelukast VersaFilm trial in Parkinson’s disease

Intrinsic Medicine developing new drugs for gut-immune-brain axis disorders

Hepion’s rencofilstat demonstrates significant reduction in liver stiffness in patients with advanced MASH liver disease

Brookline starts Annovis Bio at buy; PT $35

General

More